Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000 · View on ClinicalTrials.gov ↗
Study Summary
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Conditions Studied
Study Locations (20)
Other
- Universitätsklinikum Bonn, Klinik für Augenheilkunde — Bonn
- University Eye Hospital Tübingen — Tübingen
- Leeds Teaching Hospitals NHS Trust — Leeds
- University of Manchester - The Old St Mary's Hospital — Manchester
- Oxford Eye Hospital — Oxford
Florida
- Vitreo Retinal Associates — Gainesville
- Bascom Palmer Eye Institute — Miami
New York
- Columbia University Medical Center — New York
- CUIMC/Edward S. Harkness Eye Institute — New York
California
- Shiley Eye Institute — San Diego
Colorado
- UCHealth Sue Anschutz-Rodgers Eye Center — Aurora
Georgia
- Emory University — Atlanta
Maryland
- Wilmer Eye Institute, Johns Hopkins University MD 21287 — Baltimore
Massachusetts
- Massachusetts Eye and Ear Infirmary — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06435000
The ClinicalTrials.gov registry entry for NCT06435000 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Splice Bio, which has 29 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06435000 reports 20 study locations spanning 14 distinct geographic areas — top geographies include Other, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06435000 about?
NCT06435000 is a clinical study titled "An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene". This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
What is the current status of trial NCT06435000?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2024-03-29. Estimated completion is 2027-02.
What conditions does trial NCT06435000 study?
This clinical trial studies the following conditions: Stargardt Disease, Stargardt's Disease, STGD1, Stargardt. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06435000?
This trial is sponsored by Splice Bio, which has 29 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06435000 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.